Bevacizumab for CRVO Associated CME : Effect of Timing and Frequency of Injections on Final Visual Outcome
Joint Authors
Pikkel, Joseph
Busool, Yumna
Srour, Ward
Sharabi-Nov, Adi
Beiran, Itzchak
Chassid, Otzem
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-12-29
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Purpose.
Injection of anti-VEGF antibody into the vitreous body is a well-established treatment for ischemic central retinal vein occlusion (CRVO) associated macular edema.
Various treatment regimens regarding the timing, number, and frequency of injections have been proposed.
Methods.
We reviewed the medical records of 68 patients treated by intravitreal bevacizumab (Avastin) injections for macular edema due to CRVO.
We examined final visual acuity six months following the last injection in relation to injection policy (one primary injection followed by subsequent injections based on anatomical response versus a prescheduled protocol of one injection per month for the first 3 months) and in relation to the time lapsing from CRVO diagnosis to the first injection.
Results.
Mean visual acuity improved more for patients treated by a protocol of 3 prescheduled injections than for those treated with one primary injection.
Improvement in mean visual acuity was greater for patients who received their first injection within the first month than those treated after 3 months (P<0.01).
Conclusion.
A protocol of three prescheduled injections of bevacizumab, starting within one month of a CRVO event, was associated with better visual outcome compared to single injection and/or treatment starting more than 3 months following the time of diagnosis.
American Psychological Association (APA)
Pikkel, Joseph& Chassid, Otzem& Busool, Yumna& Srour, Ward& Sharabi-Nov, Adi& Beiran, Itzchak. 2013. Bevacizumab for CRVO Associated CME : Effect of Timing and Frequency of Injections on Final Visual Outcome. Journal of Ophthalmology،Vol. 2013, no. 2013, pp.1-4.
https://search.emarefa.net/detail/BIM-512785
Modern Language Association (MLA)
Pikkel, Joseph…[et al.]. Bevacizumab for CRVO Associated CME : Effect of Timing and Frequency of Injections on Final Visual Outcome. Journal of Ophthalmology No. 2013 (2013), pp.1-4.
https://search.emarefa.net/detail/BIM-512785
American Medical Association (AMA)
Pikkel, Joseph& Chassid, Otzem& Busool, Yumna& Srour, Ward& Sharabi-Nov, Adi& Beiran, Itzchak. Bevacizumab for CRVO Associated CME : Effect of Timing and Frequency of Injections on Final Visual Outcome. Journal of Ophthalmology. 2013. Vol. 2013, no. 2013, pp.1-4.
https://search.emarefa.net/detail/BIM-512785
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-512785